Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th Annual Congress on Clinical & Hospital Pharmacy Tokyo, Japan .

Day 2 :

Keynote Forum

Bernard M Y Cheung

University of Hong Kong, Hong Kong

Keynote: How are new drugs registered and regulated in Hong Kong, a special administrative region of China?

Time : 10:00-10:40

OMICS International Clinical Pharmacy Congress 2019 International Conference Keynote Speaker Bernard M Y Cheung photo
Biography:

Bernard M Y Cheung Completed Study from the University of Cambridge. In 2007-2009, he held the chair in Clinical Pharmacology and Therapeutics in Birmingham.He is currently the Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics at the University of Hong Kong and Heads the Division of ClinicalPharmacology and Therapeutics. He is an Honorary Consultant Physician of Queen Mary Hospital and the Medical Director of the Phase 1 Clinical Trials Centre.He is the Editor-in-Chief of Postgraduate Medical Journal. He has 270 publications, 7500 citations and an h-index of 43.

Abstract:

Hong Kong is a special administration region in Southern China enjoying a high degree of autonomy. Despite its high population density and unequal wealth distribution, infant mortality is low and life expectancy is highest in the world. The health service is however more hospital and clinic based than community-based. Primary care is largely private while over 70% of inpatient care is in public hospitals. This health infrastructure seems cost-effective. Professional standards are high and rigorously maintained. Doctors, nurses, pharmacists and other health professionals are well-remunerated even in the public sector. Drug registration follows American and European requirements. Hong Kong is part of the Pharmaceutical Inspection Co-operation Scheme, which brings with it a high standard of drug regulation. Hong Kong is a centre for clinical trials because the subjects are Chinese and protocols in English do not need to be translated. There are also two well-established clinical trials centres in university hospitals that also have a phase 1 clinical trials centre. The Hong Kong Hospital Authority is the largest customer of pharmaceuticals, and so to ensure appropriate use of drugs, there is a territory-wide drug formulary and guidelines for its hospitals and clinics, based on clinical need, and the efficacy, safety and cost-effectiveness of the drugs.